GIBSON DUNN

Gibson Dunn Advises Fairmount Funds on \$110 Million PIPE Transaction for Inhibikase Therapeutics

Firm News | October 9, 2024

Gibson, Dunn & Crutcher LLP advised Fairmount Funds on its participation in the \$110 million PIPE transaction for Inhibikase Therapeutics. The Gibson Dunn corporate team was led by partners Branden Berns and Ryan Murr.

Related People Branden C. Berns

Ryan A. Murr

Related Capabilities

Capital Markets

Emerging Companies / Venture Capital

Finance

Life Sciences

Mergers and Acquisitions

Private Equity